Quick Answer
Whitehawk Therapeutics, Inc. reported Net Income of -$20.60 million for fiscal year 2025.
Whitehawk Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$20.60M | +67.7% |
| 2024 | -$63.69M | +3.2% |
| 2023 | -$65.77M | -8.7% |
| 2022 | -$60.51M | +45.0% |
| 2021 | -$110.09M | -3065.3% |
| 2020 | -$3.48M | +85.1% |
| 2019 | -$23.27M | -123.8% |
| 2018 | -$10.40M | +51.4% |
| 2017 | -$21.40M | -26.0% |
| 2016 | -$16.98M | -53918.8% |
| 2015 | -$31.4K | -2.1% |
| 2014 | -$30.8K | -7.3% |
| 2013 | -$28.7K | -4.9% |
| 2012 | -$27.4K | -0.7% |
| 2011 | -$27.2K | -21.4% |
| 2010 | -$22.4K | -12.0% |
| 2009 | -$20.0K | +40.5% |
| 2008 | -$33.6K | -124.5% |
| 2007 | -$15.0K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$17.75M | -41.4% | +66.3% |
| June 30, 2025 | -$52.62M | -260.8% | -172.1% |
| March 31, 2025 | $73.02M | +499.2% | +682.0% |
| September 30, 2024 | -$12.55M | +23.0% | +14.0% |
| June 30, 2024 | -$14.58M | +18.9% | +20.3% |
| March 31, 2024 | -$18.29M | -20.1% | -12.2% |
| September 30, 2023 | -$16.30M | -12.6% | +9.3% |
| June 30, 2023 | -$17.97M | +1.6% | -18.1% |
- Whitehawk Therapeutics, Inc. showed an increase of +67.7% in Net Income compared to the prior fiscal year.
- Over the 2007–2025 period, Whitehawk Therapeutics, Inc.’s net income has declined by 137417.5% (from -$15.0 thousand to -$20.60 million).
- The most recent figure is from Whitehawk Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: